Currently, FDA-approved drug for ischemic stroke is the recombinant tissue plasminogen activator (r-tPA), a fibrinolytic agent, which is effective if applied within 3 h, but no longer than 4.5 h, after symptom onset (Rabinstein, 2017). The gene discussed is PLAT; the disease is ischemic stroke.